A Review Of Scott Rocklage’s Healthcare Investment Firm, 5AM Ventures

Scott Rocklage, PhD, is a managing partner at 5AM Ventures, a life science-based venture capital that invests in early stage companies. Speaking to Ideamensch, Scott said that 5AM, which is certainly early in the morning, is a reflection of their business model of investing in early stage ventures. Read more: Scott Racklage | Crunchbase

Scott works closely with entrepreneurs who have invested in the healthcare industry. The shrewd entrepreneur helps them to reach their goals by developing possible therapies for untreated health cases.

Rocklage is keen on time management, prioritization and calendaring to ensure that he stays productive. Scott believes that for one to achieve much success in entrepreneurship, he or she must take risks. He added that 5AM Ventures has achieved significant growth by not straying too far from the strengths of the business.

Lastly, Scott pointed out the new cancer treatments that target specific mutations and genotypes as a major breakthrough in the healthcare industry.

Scott Rocklage is an alumnus of the University of California, Berkeley, where he graduated with his B.S. in chemistry. He proceeded to the Massachusetts Institute of Technology (MIT) where he earned his PhD in chemistry.

Rocklage joined 5AM Ventures in 2003 as a venture partner before assuming his current role. 5AM Ventures has invested in various companies, including Novira Therapeutics, Pulmatrix, Achaogen, and Renovia. Learn more about Scott Rocklage: http://www.rennovia.com/team/scott-m-rocklage/ and http://5amventures.com/team/scott-m-rocklage-phd/

He has a deep background in healthcare management. His career has centered on strategic leadership responsibilities. Some of his achievements include the approval of three US New Drug Applications, Omniscan, Telescan, and Cubicin, by the FDA. The accomplished scientist is also responsible for clinical trials of multiple drug candidates.

Previously, Scott Rocklage served as the CEO and chairman of Cubist Pharmaceuticals. He was also the president and CEO of Nycomed Salutar. In addition, Scott served in the same capacities at Nycomed Interventional where he was also the chairman of the board.

Presently, Rocklage serves as the chairman of the boards of Relypsa, Achaogen and Semptrus. He also sits on the boards of Pulmatrix, WaveRx and Variation and the Whitehead Institute. The successful entrepreneur is the former executive chairman of Ilypsa and Miikana. The former was acquired by Amgen while the latter was purchased by EntreMed.